Kynexis

👥 17 employees💰 Last funded Dec 2022
Biotechnology Research🌐 kynexistx.com
Website LinkedIn
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
1
Frequently asked questions
Who invested in Kynexis?
Kynexis has 1 investors on record on gritt.io.
When did Kynexis last raise funding?
The most recent investment in Kynexis recorded on gritt.io was in December 2022.
What industry is Kynexis in?
Kynexis operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.